Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1

Joanne Osborne, Kristian Birchall, Denise J. Tsagris, Stephen J. Lewis, Ela Smiljanic-Hurley, Debra L. Taylor, Alison Levy, Dario Alessi, Edward G. McIver (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
97 Downloads (Pure)


Parkinson’s disease is a relatively common neurological disorder with incidence increasing with age. Present treatments merely alleviate the symptoms and do not alter the course of the disease, thus identification of disease modifying therapies represents a significant unmet medical need. Mutations in the LRRK2 gene are risk-factors for developing PD and it has been hypothesized that the increased kinase activity of certain LRRK2 mutants are responsible for the damage of the dopaminergic neurons, thus LRRK2 inhibitors offer the potential to target an underlying cause of the disease. In this communication, we describe hit-to-lead medicinal chemistry program on a novel series of 5-azaindazoles. Compound 1, obtained from high-throughput screening was optimized to a highly potent, selective series of molecules with promising DMPK properties. Introduction of heterocycles at the 3-position were found to significantly increase the potency and kinase selectivity, whilst changes to the 4-chlorobenzyl group improved the physicochemical properties. Our series was licensed to a major pharmaceutical company for further development
Original languageEnglish
Pages (from-to)668-673
Number of pages6
JournalBioorganic & Medicinal Chemistry Letters
Issue number4
Early online date1 Dec 2018
Publication statusPublished - 15 Feb 2019


  • Parkinson’s Disease
  • G2019S
  • Kinase inhibitor
  • LLE
  • Parkinson's disease

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Molecular Biology
  • Biochemistry
  • Clinical Biochemistry
  • Pharmaceutical Science
  • Organic Chemistry


Dive into the research topics of 'Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1'. Together they form a unique fingerprint.

Cite this